Results 31 to 40 of about 174,697 (145)

Identification of a novel cord blood NK cell subpopulation expressing functional programmed death receptor-1

Frontiers in Immunology, 2023
BackgroundNatural Killer cells (NKs) represent the innate counterpart of TCRαβ lymphocytes and are characterized by a high anti-tumor and an anti-viral cytotoxic activity.
Marco Greppi, Valentina Obino, Rayan Goda, Federico Rebaudi, Simona Carlomagno, Simona Carlomagno, Mariella Della Chiesa, Simona Sivori, Simona Sivori, Gianluca Ubezio, Vanessa Agostini, Alessandra Bo, Silvia Pesce, Emanuela Marcenaro, Emanuela Marcenaro   +14 more
doaj   +1 more source

Expression and clinical significance of PD-1, PD-L1 and tumor infiltrating lymphocytes in neuroblastoma

Zhongguo linchuang yanjiu
Objective To investigate the expression of programmed cell death protein 1(PD-1), programmed cell death 1 ligand 1 (PD-L1) and tumor infiltrates lymphocytes (TIL) density in neuroblastoma and the relationship between them and the clinicopathological ...
QIAO Jiahua*, HAO Ziqi, HUANG Ye, WEI Junni, LI Suhong
doaj   +1 more source

Diabetic ketoacidosis after treatment with pembrolizumab

Journal of Clinical and Translational Endocrinology Case Reports, 2017
Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with ...
M. Hariz. F. Abdul Aziz, Isuru P. Fernando, Anjan Lenkanpally, Devaka J.S. Fernando   +3 more
doaj   +1 more source

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung

Thoracic Cancer, 2022
Background A single‐agent of anti programmed cell death 1/programmed cell death ligand 1 (anti‐PD‐1/PD‐L1) therapy has been explored for resectable lung cancer before surgery.
Yuan Feng, Wei Sun, Jie Zhang, Yang Wang, Jinfeng Chen, Xinying Liu, Liang Wang, Shaolei Li, Chao Lv, Fangliang Lu, Jianzhi Zhang, Yang Hong, Shanshan Xiao, Tao Wang, Raymond Jiao, Ziping Wang, Liping Qi, Nan Li, Yue Yang, Dongmei Lin, Jian Fang   +20 more
doaj   +1 more source

Molecular Mechanism of Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma

Chinese Journal of Lung Cancer, 2018
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors were landmarks in the treatment of non-small cell lung cancer (NSCLC ...
Xuefeng LENG, Jiandong MEI, Lunxu LIU
doaj   +1 more source

Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28 [PDF]

Translational Cancer Research, 2017
T-cell inhibitory receptors balance the activation signals provided by peptide/major histocompatibility complex and costimulatory receptors (1).
Leonardo, Chicaybam, Prasad S, Adusumilli   +1 more
openaire   +2 more sources

Inhibitory Immune Checkpoints beyond Programmed Cell Death Ligand 1 in Merkel Cell Carcinoma: Abundant Expression of TIGIT Independent of the Presence of Merkel Cell Polyoma Virus

Acta Dermato-Venereologica
Merkel cell carcinoma is a rare, aggressive skin cancer in which Merkel cell polyoma virus (MCPyV) is frequently pathogenically involved. After failure of anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy, therapeutic ...
Ferdinand Toberer, Julia K. Winkler, Leroy Atienza Fernandez, Lea Adams, Alexander Brobeil, Marcell Tóth, Alexander H. Enk, Jürgen C. Becker, Anke Lonsdorf   +8 more
doaj   +1 more source

Regulation of Trypanosoma cruzi-Induced Myocarditis by Programmed Death Cell Receptor 1 [PDF]

Infection and Immunity, 2011
ABSTRACTTrypanosoma cruziinfection causes intense myocarditis, leading to cardiomyopathy and severe cardiac dysfunction. Protective adaptive immunity depends on balanced signaling through a T cell receptor and coreceptors expressed on the T cell surface.
Fredy R S, Gutierrez, Flávia S, Mariano, Carlo J F, Oliveira, Wander R, Pavanelli, Paulo M M, Guedes, Grace K, Silva, Ana P, Campanelli, Cristiane M, Milanezi, Miyuki, Azuma, Tasuku, Honjo, Mauro M, Teixeira, Julio C S, Aliberti, João S, Silva   +12 more
openaire   +2 more sources

Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report

JTO Clinical and Research Reports
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is
Ken Yamamoto, MD, Katsuya Hirano, MD, Temiko Shimada, MD, PhD, Akito Hata, MD   +3 more
doaj   +1 more source

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis

Iranian Journal of Allergy, Asthma and Immunology, 2016
Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2, have been regarded as important immune system regulatory molecules. The aberrant expression of the molecules has been related to several autoimmune disorders.
Mohammad Reza Javan, Saeed Aslani, Mohammad Reza Zamani, Javad Rostamnejad, Milad Asadi, Mahdi Farhoodi, Mohammad Hossein Nicknam   +6 more
doaj